"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • For Professionals
  • Drug Updates
  • Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

10 Jun 2022 1:30 PM | Katy Monaco (Administrator)

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported new data further underscoring the significant burden of disease in adults with pyruvate kinase (PK) deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients.  Read More.

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software